Abstract
Background. Cerebral palsy (CP) is a severe disabling disease with worldwide incidence being 2 to 3 per 1000 live births. CP was considered as a noncurable, nonreparative disorder, but stem cell therapy offers a potential treatment for CP. Objective. The present study evaluates the safety and efficacy of autologous bone-marrow-derived mononuclear cell (BMMNCs) transplantation in CP patient. Material and Methods. In the present study, five infusions of autologous stem cells were injected intrathecally. Changes in neurological deficits and improvements in function were assessed using Gross Motor Function Classification System (GMFCS-E&R) scale. Results. Significant motor, sensory, cognitive, and speech improvements were observed. Bowel and bladder control has been achieved. On the GMFCS-E&R level, the patient was promoted from grade III to I. Conclusion. In this study, we report that intrathecal infusion of autologous BMMNCs seems to be feasible, effective, and safe with encouraging functional outcome improvements in CP patient.
Highlights
Cerebral palsy (CP) is the commonest cause of severe neurological disability in children
Magnetic resonance imaging (MRI) brain was performed which showed clinical impression of large head circumference, persistent cavum septum pellucidum, and no focal lesions within brain parenchyma. She had delayed milestones when examined at the age of 11 months and was diagnosed with cerebral palsy
We provide the evidence of feasibility and efficacy of BMMNCs transplantation in CP
Summary
CP is the commonest cause of severe neurological disability in children. The general prevalence is 2-3 per 1000 live births and has slightly increased in recent years. Treatment programs for CP encompass physical and behavioral therapy, pharmacologic and surgical treatments, mechanical aids, and management of associated medical conditions. Recent advances in stem cell therapy provide the hope of developing more effective interventions in treating CP. Stem cell transplantation has been reported to be effective in animal models as well as in patients with other degenerative neurological disorders such as stroke and demyelination [6,7,8]. The present study evaluates the safety and efficacy of autologous bone-marrow-derived mononuclear cell (BMMNCs) transplantation in CP patient. We report that intrathecal infusion of autologous BMMNCs seems to be feasible, effective, and safe with encouraging functional outcome improvements in CP patient
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
